Regression of brain metastases from breast cancer with eribulin: a case report

BACKGROUND: Eribulin is a recently approved new therapeutic option for patients with metastatic breast cancer. According to several reports, eribulin has limited ability to cross the blood brain barrier. Recently, capecitabine and eribulin have been recognized as drugs with similar application for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuoka, Hiromichi, Tsurutani, Junji, Tanizaki, Junko, Iwasa, Tsutomu, Komoike, Yoshifumi, Koyama, Atsuko, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878316/
https://www.ncbi.nlm.nih.gov/pubmed/24350786
http://dx.doi.org/10.1186/1756-0500-6-541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878316/
https://www.ncbi.nlm.nih.gov/pubmed/24350786
http://dx.doi.org/10.1186/1756-0500-6-541

Ejemplares similares